Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029819 | 0.85 | ALDH1A1 (0.46) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL24029890 | 0.82 | CHRM2 (0.44) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL26550984 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL24029610 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL24029902 | 0.75 | GAA (0.45) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL24029899 | 0.74 | SIGMAR1 (0.40) | CHRM2CHRM4CHRM1CHRM3ALDH1A1 | |
| SCHEMBL24030165 | 0.73 | MAPT (0.38) | MEN1KMT2ACTSDCTSLCTSB | |
| SCHEMBL9106442 | 0.70 | HPGD (0.41) | CTSLCTSB | |
| SCHEMBL19853105 | 0.69 | HPGD (0.43) | MEN1KMT2ACTSLCTSB | |
| SCHEMBL24029771 | 0.67 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2021227440-A1 | A CLASS OF ARYL GLUCOSIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | CHRM2 4157/4885CHRM4 4182/4885CHRM1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.